MediClin Reports Impressive Group Sales of €730.1M in 2023, Forecasts Positive 2024 Outlook

• MEDICLIN achieved consolidated Group sales of EUR 730.1 million in 2023, a 3.6% increase compared to 2022.
• The Group operating result was EUR 12.7 million, EUR 6.8 million below the previous year's figure due to a one-off effect.
• The outlook for 2024 is positive due to stable capacity utilisation rates.
• Sales in the post-acute segment were € 451.2 million, a 4.6% increase from the previous year.
• Sales in the acute segment totalled EUR 254.0 million, a 0.5% increase compared to the previous year.
• The Executive Board anticipates sales growth for the Group of 3.0% to 5.0% in 2024, with Group EBIT expected to be between 38.0 million euros and 46.0 million euros.

The price of MEDICLIN at the time of the news was 2,3400EUR and was up +0,43 % compared with the previous day.
12 minutes after the article was published, the price was 2,5000EUR this corresponds to a plus of +6,84 % since publication.

MEDICLIN

0,00 %

+6,82 %

+17,50 %

+7,63 %

-6,00 %

-33,18 %

-47,78 %

-74,48 %

ISIN:DE0006595101WKN:659510

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max